HLD-0915, a RIPTACT therapeutic, targets mCRPC by linking the androgen receptor with an effector protein, disrupting cancer cell functions. The phase 1/2 trial will evaluate HLD-0915's safety, ...
Add Yahoo as a preferred source to see more of our stories on Google. PARIS — Investment fund HLD has entered into exclusive talks with the founders of Jimmy Fairly and Experienced Capital to acquire ...
TORONTO--(BUSINESS WIRE)--Highland Therapeutics Inc.’s wholly owned subsidiary, Ironshore Pharmaceuticals & Development, Inc. (“Ironshore”), today announced positive clinical data from the second ...
We’ve had plenty of exits to report this week, glimmers of light amid what is still a dulled sale environment. First up is Groupe HLD-backed Exosens, as we look at how the optical component company’s ...
PARIS — Investment fund HLD has entered into exclusive talks with the founders of Jimmy Fairly and Experienced Capital to acquire a majority stake in the French eyewear brand. Terms of the deal were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results